CRMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

127.52M

+308.6%

0.840

+281.82%

127.41M

+226.02%

0.720

+140%

127.57M

+221.04%

0.720

+157.14%

Estimates Revision

The market is revising Upward the revenue expectations for CorMedix Inc. (CRMD) for FY2025, with the revenue forecasts being adjusted by 24.88% over the past three months. During the same period, the stock price has changed by -30.64%.

Revenue Estimates for FY2025

Revise Upward

+24.88%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+51.67%

In Past 3 Month

Stock Price

Go Down

-30.64%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 18.40 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

14.00

Averages

18.40

High

22.00

Current: 0.000

Low

14.00

Averages

18.40

High

22.00

Truist

Buy

maintain

$20 -> $16

2026-01-08

New

Reason

Truist

Price Target

$20 -> $16

2026-01-08

New

maintain

Buy

Reason

Truist lowered the firm's price target on CorMedix to $16 from $20 and keeps a Buy rating on the shares after the company introduced a FY26 revenue guidance roughly 40% below the Street and 2027 DefenCath revenue guidance at roughly half the firm's initial estimate. This marks a significantly greater tail off for DefenCath than the firm and Wall Street have factored, the analyst tells investors in a research note. The firm added that it expects to hear more from the company at an upcoming Investor day on February 10.

H.C. Wainwright

Brandon Folkes

Buy

maintain

$17 -> $18

2025-11-13

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$17 -> $18

2025-11-13

maintain

Buy

Reason

H.C. Wainwright analyst Brandon Folkes raised the firm's price target on CorMedix to $18 from $17 and keeps a Buy rating on the shares post the Q3 report. With the acquisition of Melinta now closed, CorMedix has a more diversified business going into 2026, the analyst tells investors in a research note.

RBC Capital

Gregory Renza

Outperform

maintain

$21 -> $22

2025-10-21

Reason

RBC Capital

Gregory Renza

Price Target

$21 -> $22

2025-10-21

maintain

Outperform

Reason

RBC Capital analyst Gregory Renza raised the firm's price target on CorMedix to $22 from $21 and keeps an Outperform rating on the shares. CorMedix raised their pro-forma 2025 revenue guidance to $375M+ and reported an $85M+ quarter for DefenCath, showing strong quarter over quarter growth for DefenCath, the analyst tells investors in a research note. DefenCath still has room to grow within existing dialysis organizations and the post-TDAPA cliff is manageable, the firm argues.

Boral Capital

D. Boral

Hold

Buy

upgrade

$14

2025-10-20

Reason

Boral Capital

D. Boral

Price Target

$14

2025-10-20

upgrade

Hold

Buy

Reason

D. Boral Capital upgraded CorMedix to Buy from Hold with a $14 price target after the company reported preliminary Q3 results. The "robust" sales in Q3 and visibility into near-term operating synergies, as well as the recent stock pullback, lead the firm to raise its rating and reinstate its $14 target.

H.C. Wainwright

Brandon Folkes

Buy

downgrade

$20 -> $17

2025-08-08

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$20 -> $17

2025-08-08

downgrade

Buy

Reason

H.C. Wainwright analyst Brandon Folkes lowered the firm's price target on CorMedix to $17 from $20 and keeps a Buy rating on the shares. The firm views the acquisition of Melinta Therapeutics as neutral.

H.C. Wainwright

Brandon Folkes

Buy

initiated

$20

2025-06-30

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$20

2025-06-30

initiated

Buy

Reason

H.C. Wainwright analyst Brandon Folkes initiated coverage of CorMedix with a Buy rating and $20 price target. CorMedix received FDA approval for DefenCath in late 2023 and has outperformed expectations on the DefenCath launch to date, argues the analyst, who sees "unappreciated upside still to be unlocked." The company is in the initial t year TDAP period, and will enjoy a further three years post this initial period of reimbursement, adds the analyst, who thinks revenue potential post the initial TDAPA period "remains underappreciated."

Valuation Metrics

The current forward P/E ratio for CorMedix Inc (CRMD.O) is 4.34, compared to its 5-year average forward P/E of -4.73. For a more detailed relative valuation and DCF analysis to assess CorMedix Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.73

Current PE

4.34

Overvalued PE

35.90

Undervalued PE

-45.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

1.23

Current EV/EBITDA

3.78

Overvalued EV/EBITDA

8.47

Undervalued EV/EBITDA

-6.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4085.23

Current PS

1.95

Overvalued PS

18284.11

Undervalued PS

-10113.66

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CRMD News & Events

Events Timeline

No data

News

1.0

01-09Globenewswire

CorMedix to Present Corporate Overview at 44th J.P. Morgan Healthcare Conference

8.0

01-08NASDAQ.COM

CorMedix and GM See Significant Options Trading Volume Surge

4.0

01-08Benzinga

U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction

People Also Watch

Frequently Asked Questions

What is CorMedix Inc (CRMD) stock price today?

The current price of CRMD is 7.63 USD — it has increased 1.6 % in the last trading day.

What is CorMedix Inc (CRMD)'s business?

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

What is the price predicton of CRMD Stock?

What is CorMedix Inc (CRMD)'s revenue for the last quarter?

CorMedix Inc revenue for the last quarter amounts to 104.28M USD, increased 810.22 % YoY.

What is CorMedix Inc (CRMD)'s earnings per share (EPS) for the last quarter?

CorMedix Inc. EPS for the last quarter amounts to 1.26 USD, decreased -2620.00 % YoY.

What changes have occurred in the market's expectations for CorMedix Inc (CRMD)'s fundamentals?

How many employees does CorMedix Inc (CRMD). have?

CorMedix Inc (CRMD) has 64 emplpoyees as of January 10 2026.

What is CorMedix Inc (CRMD) market cap?

Today CRMD has the market capitalization of 601.16M USD.